Bioject Medical Technologies Inc., a leading innovator in the medical device industry, is headquartered in the United States. Founded in 1986, the company has established itself as a pioneer in needle-free injection technology, significantly enhancing patient comfort and safety. With a focus on developing advanced drug delivery systems, Bioject's core products include the Biojector® device, which offers a unique, efficient method for administering vaccines and medications without the use of needles. Operating primarily in North America and expanding into international markets, Bioject has achieved notable milestones, including partnerships with major pharmaceutical companies. The company’s commitment to innovation and quality has positioned it as a trusted name in the healthcare sector, making significant contributions to the evolution of drug delivery solutions.
How does Bioject Medical Technologies Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Bioject Medical Technologies Inc.'s score of 17 is lower than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Bioject Medical Technologies Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Bioject Medical Technologies may not have established formal commitments to reduce its carbon footprint or engage in industry-standard climate initiatives. In the context of the medical technology sector, companies are increasingly expected to adopt transparent climate strategies and set measurable targets for emissions reductions. Without such commitments or data, Bioject Medical Technologies may face challenges in aligning with industry best practices and stakeholder expectations regarding sustainability and climate action.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Bioject Medical Technologies Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
